Takeuchi M, et al. - Researchers examined how neoadjuvant therapy influenced poor long-term outcomes of postoperative complications in patients with esophageal carcinoma. They identified and categorized 431 patients into two groups: the neoadjuvant therapy (+) group (n = 217) and neoadjuvant therapy (−) group (n = 214). Multivariate analysis indicated pneumonia, pyothorax, and chylothorax as predictors of death in the neoadjuvant therapy (−) group. The findings emphasize performing neoadjuvant therapy in patients with esophageal carcinoma to reduce the negative impact of postoperative complications on long-term prognoses.